Wuhan Createrna Science and Technology Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO17%
Delay Index: of 6 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Wuhan Createrna Science and Technology Co., Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MY008211A tablets NCT06932744 |
P3 | Recruiting | Paroxysmal Nocturnal Haemoglobinuria (PNH) | 66 | 2025-12-30 |
| MY008211A tablets NCT06932471 |
P3 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria | 20 | 2025-12-30 |
| QR12000 75mg NCT06716970 |
P3 | Not yet recruiting | Essential Hypertension | 810 | 2026-04-30 |
| MY008211A tablets NCT06687174 |
P2 | Not yet recruiting | IgA Nephropathy (IgAN) | 72 | 2026-06-15 |
| MY008211A tablets NCT06933914 |
P2/3 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 120 | 2026-12-30 |
| MY008211A tablets NCT06134414 |
P2 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 40 | 2027-07 (+24 mo) |